Tony Hagen

The median overall survival for patients with chronic lymphocytic leukemia has more than tripled since the 1970s, primarily due to an ever-expanding armamentarium of novel agents and earlier diagnosis.

The fast pace of development in the immunotherapy and targeted therapy space has outstripped the availability of head-to-head comparative data for adjuvant melanoma treatment. Therefore, Hussein Tawbi, MD, PhD, recommended for healthcare professionals to communicate the relative merits and risks of both options to patients and making a shared decision.

Endocrine therapy can reduce tumor size in patients with ER-positive breast cancer. It can even help some patients avoid chemotherapy or even surgery. Deciding how long to continue this therapy can be tricky though.

The latest revision of the staging manual for breast cancer from the American Joint Committee on Cancer (AJCC) codifies advanced knowledge of the role of biologic factors in cancer.

Palbociclib (Ibrance), a CDK 4/6 inhibitor, demonstrated significant efficacy in combination with the aromatase inhibitor letrozole (Femara) in the frontline setting of estrogen receptor (ER)-positive, HER2-negative, postmenopausal metastatic breast cancer in phase III PALOMA-2 study.

Tisagenlecleucel (Kymriah), Novartis' newly approved CAR T-cell therapy, will be put on the market with a price of $475,000 for a single infusion, an amount that is within the range anticipated by oncologists and that Novartis characterized as well below a price level that could be justified on cost.

“If you locked everybody in a room for a week, I think we could come up with something that everybody would be comfortable with,” said Blase Polite, MD, a co-author of the statement, and immediate past chair of ASCO’s government relations committee.

Members of the ACCC have created an online course, Financial Advocacy Boot Camp, to help financial navigators find the funds for their patients.

The revised American Health Care Act has passed through the House of Representatives.

At the 2017 Community Oncology Alliance annual conference, panelists discussed techniques to encourage improved adherence in patients on oral oncology medication.

The FDA has expanded the approval of bevacizumab to include platinum-sensitive recurrent ovarian cancer.

Drawing a standing ovation from a packed room of oncology professionals attending the 33rd Annual Miami Breast Cancer Conference®, breast cancer survivor and Good Morning America news anchor Amy Robach criticized new US Preventive Services Task Force guidelines that extend the recommended age to begin mammogram screening to age 50 for women at average risk.

Feelings of social isolation and financial toxicity take an especially high toll on patients with LAHNC, and assessing patients for these issues is essential to achieve optimal care.

A group of 118 well-known cancer experts have come together to spotlight the escalating costs of cancer treatment with an aim to galvanize patients and grassroots advocates to make their voices heard.

The possibility of going bankrupt is high on the list of concerns for 37.1% of cancer patients who participated in a recently published survey by the Washington, DC-based Cancer Support Community (CSC), an international nonprofit.